Evaluate the Safety and Performance of the AccuCinch® Ventricular Repair System - The CorCinch-EU Study

NAActive, not recruitingINTERVENTIONAL
Enrollment

132

Participants

Timeline

Start Date

January 15, 2019

Primary Completion Date

October 31, 2026

Study Completion Date

December 31, 2027

Conditions
Heart FailureCardiomyopathies
Interventions
DEVICE

Left ventricular restoration

The AccuCinch® Ventricular Repair System, implanted in the sub-valvular space of the left ventricle, is intended to reduce significant symptomatic mitral regurgitation and reverse left ventricular remodeling due to dilated cardiomyopathy of either ischemic or non-ischemic etiology via percutaneous interventional methods.

Trial Locations (19)

8091

University Hospital Zurich, Zurich

9300

Onze Lieve Vrouwziekenhuis, Aalst

10800

AZ Sint-Jan Brugge, Bruges

13005

Hôpital de La Timone, Marseille

15030

Na Homolce Hospital, Prague

20037

IRCCS Policlinico San Donato, Milan

20132

Ospedale San Raffaele, Milan

33600

Pessac (CHU Bordeaux), Pessac

48033

Maria Cecilia Hospital, Cotignola

67000

Hôpital Civil de Strasbourg, Strasbourg

69500

Hôpital Cardio-Vasculaire Louis Pradel, Bron

75013

Paris Hôpital de la Pitié-Salpêtrière, Paris

220036

Republican Scientific and Practical Centre of Cardiology, Minsk

Unknown

Clinique Pasteur, Toulouse

St. Antonius Ziekenhuis, Nieuwegein

08661

Vilnius University Hospital Santaros Klinikos, Vilnius

3015 GD

Erasmus Medical Center, Rotterdam

02-097

Medical University of Warsaw, Warsaw

SW3 6NP

Royal Brompton & Harefield NHS Trust, London

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Ancora Heart, Inc.

INDUSTRY

NCT03183895 - Evaluate the Safety and Performance of the AccuCinch® Ventricular Repair System - The CorCinch-EU Study | Biotech Hunter | Biotech Hunter